Oncodesign SA

Oncodesign SA is a France-based company that discovers and develops therapies against cancer. The Company's services include target identification, validation and cellular screens; preclinical research, in vivo screening and pharmacology; molecular pharmacology and biomarkers, pharmaco-imaging and immunology, among others. Its activities include preclinical evaluation services and discovery operations. The Company's technologies include Predict, Chi-Mice, Pharm'Image and Nanocyclix. Its technological platform offers solutions for pharmaceutical and biotechnology companies.
  • TickerA1107T
  • ISINFR0011766229
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Gilbert Ferrand

ONCODESIGN SA. Net Results 2018 (+). Perfect cost and cash control

ONCODESIGN SA. Net Results 2018 (+). Perfect cost and cash control

Gilbert Ferrand

ONCODESIGN SA - Collaboration stratégique dans la maladie de Parkinson (+) Recherche de candidats médicament contre Parkinson en partenariat avec Servier.

ONCODESIGN SA - Collaboration stratégique dans la maladie de Parkinson (+) Recherche de candidats médicament contre Parkinson en partenariat avec Servier.

Gilbert Ferrand

ONCODESIGN SA - CA 2018 (=) Très forte dynamique.

ONCODESIGN SA - CA 2018 (=) Très forte dynamique.

Gilbert Ferrand

ONCODESIGN SA. Net Results 2018 (+). Perfect cost and cash control

ONCODESIGN SA. Net Results 2018 (+). Perfect cost and cash control

Gilbert Ferrand

ONCODESIGN SA - Collaboration stratégique dans la maladie de Parkinson (+) Recherche de candidats médicament contre Parkinson en partenariat avec Servier.

ONCODESIGN SA - Collaboration stratégique dans la maladie de Parkinson (+) Recherche de candidats médicament contre Parkinson en partenariat avec Servier.

Gilbert Ferrand

ONCODESIGN SA - CA 2018 (=) Très forte dynamique.

ONCODESIGN SA - CA 2018 (=) Très forte dynamique.

Gilbert Ferrand

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

ONCODESIGN SA. Net results H1 2018. Balance sheet and operating result under control

Gilbert Ferrand

ONCODESIGN SA. RN S1 2018. Bilan et soldes de gestion maîtrisés

ONCODESIGN SA. RN S1 2018. Bilan et soldes de gestion maîtrisés

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch